Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical pharmaceutical company developing injection-based treatments against chronic pain originating from the intevertebral discs. Stayble currently has one phase 2b project within degenerative disc disease and one phase 1b within disc herniation.
LATEST PRESS RELEASES
Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023
Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...
Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study
Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...